Evidence map›Paper›PMID 33472452›Full record

ArticleExpert opinion on drug discovery2021

From leptin to lasers: the past and present of mouse models of obesity.

Joshua R Barton, Adam E Snook, Scott A Waldman

Open access · greenAbstract read
In one paragraph

Article in Expert opinion on drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Joshua R BartonDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia USA.ORCID 0000-0003-3690-6624
Adam E SnookDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia USA.ORCID 0000-0001-9216-4560
Scott A WaldmanDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia USA.
Thomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
Guanylin GUCY2C axis in Colorectal Cancer InitiationR01CA204481 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2017 to 2021
$1.8M
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformationR01CA206026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2016 to 2020
$1.8M
Silencing the uroguanylin-GUCY2C gut-brain axis mediates leptin resistance in obesityF30DK127639 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI BARTON, JOSHUA R · 2020 to 2024
$175k
NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA204481NCI NIH HHS R01 CA206026NIDDK NIH HHS F30 DK127639
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain-Gut AxisLeptinAnimalsAppetiteLasersMiceObesityLeptinAnimal modelsanti-obesity drugsappetitegut-brain axisleptinleptin resistancemouse modelsneuromodulationobesitysyndromic obesity

Identifiers

PMID33472452
PMCPMC8243785
OpenAlexW3125515571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.